Tag: Melanoma

Stock

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

01/06/2025
admin

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma…

Finance News

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

27/01/2025
admin

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma #Erasca039s #Naporafenib #Shaping #Nicely #NRASm #Melanoma